| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cells | 99 | 2025 | 563 | 18.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 30 | 2025 | 160 | 9.170 |
Why?
|
| Hematopoiesis | 33 | 2025 | 227 | 7.290 |
Why?
|
| DNA Methylation | 32 | 2025 | 1144 | 5.800 |
Why?
|
| Cell Differentiation | 51 | 2025 | 2027 | 4.190 |
Why?
|
| Stem Cells | 25 | 2025 | 750 | 4.180 |
Why?
|
| Bone Marrow Cells | 27 | 2015 | 273 | 3.170 |
Why?
|
| Protein Phosphatase 2C | 6 | 2024 | 60 | 2.800 |
Why?
|
| Cellular Senescence | 10 | 2025 | 201 | 2.760 |
Why?
|
| Epigenesis, Genetic | 20 | 2023 | 774 | 2.750 |
Why?
|
| Mutation | 33 | 2025 | 6267 | 2.710 |
Why?
|
| Leukemia, Myeloid, Acute | 12 | 2024 | 567 | 2.710 |
Why?
|
| Mice | 124 | 2025 | 18815 | 2.550 |
Why?
|
| Hematologic Neoplasms | 8 | 2022 | 296 | 2.520 |
Why?
|
| Animals | 154 | 2025 | 36265 | 2.460 |
Why?
|
| Cell Separation | 19 | 2013 | 234 | 2.450 |
Why?
|
| Flow Cytometry | 19 | 2013 | 835 | 1.900 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2025 | 612 | 1.870 |
Why?
|
| Cell Lineage | 20 | 2025 | 369 | 1.840 |
Why?
|
| Bone Marrow | 12 | 2020 | 334 | 1.790 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2024 | 80 | 1.780 |
Why?
|
| Adult Stem Cells | 4 | 2015 | 54 | 1.740 |
Why?
|
| Neoplasm Proteins | 9 | 2024 | 717 | 1.720 |
Why?
|
| Gene Editing | 5 | 2019 | 202 | 1.700 |
Why?
|
| Gene Expression Regulation | 16 | 2020 | 2658 | 1.660 |
Why?
|
| DNA-Binding Proteins | 11 | 2025 | 2157 | 1.590 |
Why?
|
| Mice, Inbred C57BL | 52 | 2025 | 4786 | 1.560 |
Why?
|
| Cell Proliferation | 23 | 2020 | 2535 | 1.540 |
Why?
|
| Mosaicism | 2 | 2024 | 245 | 1.530 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2020 | 645 | 1.510 |
Why?
|
| Dioxygenases | 7 | 2025 | 64 | 1.440 |
Why?
|
| Bone Marrow Transplantation | 20 | 2015 | 621 | 1.410 |
Why?
|
| DNA Modification Methylases | 3 | 2022 | 52 | 1.360 |
Why?
|
| Clonal Evolution | 5 | 2025 | 49 | 1.320 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 6 | 2015 | 406 | 1.300 |
Why?
|
| Nuclear Proteins | 6 | 2020 | 1328 | 1.260 |
Why?
|
| CRISPR-Cas Systems | 5 | 2024 | 283 | 1.260 |
Why?
|
| Histones | 9 | 2022 | 567 | 1.250 |
Why?
|
| Gene Expression Regulation, Leukemic | 7 | 2019 | 69 | 1.210 |
Why?
|
| Gene Expression Profiling | 14 | 2023 | 1911 | 1.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2025 | 1190 | 1.060 |
Why?
|
| Aging | 9 | 2025 | 1298 | 1.030 |
Why?
|
| Benzimidazoles | 14 | 2011 | 136 | 1.000 |
Why?
|
| Promoter Regions, Genetic | 6 | 2019 | 1413 | 1.000 |
Why?
|
| Homeodomain Proteins | 5 | 2021 | 585 | 0.990 |
Why?
|
| Clone Cells | 3 | 2025 | 177 | 0.980 |
Why?
|
| Mice, Knockout | 22 | 2024 | 3957 | 0.960 |
Why?
|
| Leukemia | 5 | 2024 | 377 | 0.950 |
Why?
|
| Antigens, CD | 5 | 2011 | 451 | 0.950 |
Why?
|
| GTP-Binding Proteins | 3 | 2011 | 188 | 0.950 |
Why?
|
| Humans | 107 | 2025 | 133290 | 0.940 |
Why?
|
| Megakaryocytes | 1 | 2025 | 45 | 0.930 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 317 | 0.930 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2024 | 25 | 0.900 |
Why?
|
| Embryonic Stem Cells | 6 | 2013 | 176 | 0.890 |
Why?
|
| Leukocyte Common Antigens | 13 | 2016 | 93 | 0.890 |
Why?
|
| Nitriles | 1 | 2024 | 155 | 0.860 |
Why?
|
| RNA, Long Noncoding | 4 | 2020 | 245 | 0.850 |
Why?
|
| Muscle, Skeletal | 12 | 2023 | 1050 | 0.850 |
Why?
|
| Myeloid Cells | 5 | 2025 | 119 | 0.840 |
Why?
|
| Gene Expression Regulation, Developmental | 8 | 2020 | 1048 | 0.820 |
Why?
|
| Chromatin | 6 | 2020 | 609 | 0.820 |
Why?
|
| Antigens, Ly | 8 | 2012 | 35 | 0.800 |
Why?
|
| Cell Cycle | 8 | 2020 | 628 | 0.790 |
Why?
|
| Embryonic Development | 1 | 2024 | 220 | 0.780 |
Why?
|
| Side-Population Cells | 2 | 2013 | 12 | 0.770 |
Why?
|
| Pyrimidines | 2 | 2024 | 419 | 0.760 |
Why?
|
| Pyrazoles | 1 | 2024 | 326 | 0.750 |
Why?
|
| Genomic Imprinting | 2 | 2013 | 129 | 0.740 |
Why?
|
| Cells, Cultured | 18 | 2018 | 3171 | 0.720 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 793 | 0.710 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2022 | 121 | 0.700 |
Why?
|
| Fires | 1 | 2020 | 12 | 0.680 |
Why?
|
| Environment | 1 | 2021 | 155 | 0.670 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2020 | 129 | 0.660 |
Why?
|
| Obesity, Morbid | 1 | 2022 | 211 | 0.640 |
Why?
|
| Hematologic Diseases | 1 | 2019 | 83 | 0.610 |
Why?
|
| Membrane Proteins | 9 | 2012 | 1607 | 0.600 |
Why?
|
| Stem Cell Transplantation | 11 | 2007 | 250 | 0.600 |
Why?
|
| Mouse Embryonic Stem Cells | 1 | 2018 | 36 | 0.590 |
Why?
|
| Signal Transduction | 11 | 2019 | 4881 | 0.590 |
Why?
|
| Neoplasms | 6 | 2025 | 3006 | 0.580 |
Why?
|
| Regeneration | 7 | 2015 | 231 | 0.570 |
Why?
|
| Intellectual Disability | 2 | 2022 | 1076 | 0.570 |
Why?
|
| Transgenes | 3 | 2008 | 345 | 0.570 |
Why?
|
| Environmental Exposure | 1 | 2019 | 244 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 406 | 0.550 |
Why?
|
| Doxorubicin | 1 | 2018 | 305 | 0.550 |
Why?
|
| Transplantation Conditioning | 3 | 2015 | 299 | 0.540 |
Why?
|
| Multipotent Stem Cells | 5 | 2025 | 29 | 0.540 |
Why?
|
| Cisplatin | 1 | 2018 | 284 | 0.530 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2017 | 957 | 0.530 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 349 | 0.530 |
Why?
|
| Gene Regulatory Networks | 3 | 2015 | 396 | 0.530 |
Why?
|
| Receptors, Erythropoietin | 1 | 2016 | 13 | 0.520 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 1801 | 0.520 |
Why?
|
| Whole Genome Sequencing | 2 | 2025 | 327 | 0.520 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 30 | 0.510 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 1326 | 0.510 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 795 | 0.510 |
Why?
|
| Inflammation | 3 | 2020 | 1599 | 0.510 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2011 | 1069 | 0.500 |
Why?
|
| HEK293 Cells | 6 | 2021 | 804 | 0.500 |
Why?
|
| CpG Islands | 6 | 2017 | 347 | 0.500 |
Why?
|
| Cell Division | 11 | 2011 | 772 | 0.490 |
Why?
|
| Health | 1 | 2015 | 38 | 0.490 |
Why?
|
| Methyltransferases | 1 | 2016 | 78 | 0.490 |
Why?
|
| Tuberculosis | 3 | 2011 | 551 | 0.490 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 120 | 0.480 |
Why?
|
| Carcinogenesis | 1 | 2018 | 361 | 0.480 |
Why?
|
| Cesium Radioisotopes | 1 | 2015 | 8 | 0.480 |
Why?
|
| X-Rays | 1 | 2015 | 30 | 0.480 |
Why?
|
| Green Fluorescent Proteins | 5 | 2008 | 397 | 0.480 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 119 | 0.480 |
Why?
|
| Antineoplastic Agents | 5 | 2025 | 1844 | 0.460 |
Why?
|
| Lymphoma | 2 | 2023 | 335 | 0.450 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2015 | 171 | 0.450 |
Why?
|
| Fluorescent Dyes | 11 | 2011 | 270 | 0.440 |
Why?
|
| DNA Damage | 4 | 2025 | 542 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 2114 | 0.430 |
Why?
|
| Immunity | 3 | 2011 | 189 | 0.430 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2014 | 93 | 0.430 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 45 | 0.420 |
Why?
|
| Cell Culture Techniques | 5 | 2015 | 292 | 0.410 |
Why?
|
| Cell Line | 7 | 2020 | 2842 | 0.410 |
Why?
|
| Alleles | 4 | 2011 | 1703 | 0.410 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2012 | 6 | 0.400 |
Why?
|
| Rejuvenation | 2 | 2022 | 12 | 0.400 |
Why?
|
| Homeostasis | 4 | 2011 | 751 | 0.400 |
Why?
|
| Central Nervous System | 2 | 2025 | 283 | 0.400 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2012 | 16 | 0.390 |
Why?
|
| Protein Isoforms | 3 | 2022 | 427 | 0.390 |
Why?
|
| Tetraspanin 28 | 1 | 2011 | 2 | 0.380 |
Why?
|
| Chemokine CCL5 | 1 | 2012 | 53 | 0.370 |
Why?
|
| Pluripotent Stem Cells | 3 | 2013 | 77 | 0.370 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 3719 | 0.370 |
Why?
|
| Receptors, Interferon | 1 | 2011 | 25 | 0.370 |
Why?
|
| Organ Specificity | 5 | 2015 | 441 | 0.370 |
Why?
|
| DNA Repair | 4 | 2023 | 627 | 0.370 |
Why?
|
| Fibroblasts | 2 | 2019 | 928 | 0.370 |
Why?
|
| Ataxia | 1 | 2013 | 177 | 0.360 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 188 | 0.360 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 40 | 0.360 |
Why?
|
| Alchemy | 1 | 2011 | 3 | 0.360 |
Why?
|
| Blood Cells | 2 | 2025 | 55 | 0.360 |
Why?
|
| Epigenomics | 3 | 2018 | 195 | 0.360 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2020 | 315 | 0.360 |
Why?
|
| Colony-Forming Units Assay | 7 | 2010 | 70 | 0.360 |
Why?
|
| Dermis | 1 | 2011 | 27 | 0.350 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2010 | 33 | 0.350 |
Why?
|
| Intestine, Small | 1 | 2013 | 317 | 0.350 |
Why?
|
| Cell Fusion | 4 | 2005 | 38 | 0.350 |
Why?
|
| Science | 1 | 2011 | 37 | 0.340 |
Why?
|
| Biomarkers | 9 | 2020 | 3402 | 0.340 |
Why?
|
| Genome, Human | 2 | 2017 | 1347 | 0.340 |
Why?
|
| Mice, Transgenic | 8 | 2024 | 2525 | 0.330 |
Why?
|
| Phenotype | 11 | 2012 | 4518 | 0.330 |
Why?
|
| Doxycycline | 2 | 2008 | 121 | 0.330 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 314 | 0.330 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2010 | 40 | 0.330 |
Why?
|
| Antigens, CD34 | 4 | 2007 | 111 | 0.330 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 324 | 0.320 |
Why?
|
| Leukemia, Experimental | 2 | 2020 | 17 | 0.320 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2022 | 62 | 0.320 |
Why?
|
| Autistic Disorder | 1 | 2013 | 363 | 0.320 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1705 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 3471 | 0.320 |
Why?
|
| Cell Transplantation | 5 | 2010 | 45 | 0.320 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 141 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 270 | 0.310 |
Why?
|
| Models, Animal | 1 | 2011 | 480 | 0.310 |
Why?
|
| CCCTC-Binding Factor | 2 | 2020 | 22 | 0.310 |
Why?
|
| Apoptosis | 6 | 2016 | 1931 | 0.310 |
Why?
|
| Leukemia, Myeloid | 2 | 2015 | 82 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 514 | 0.300 |
Why?
|
| Genes, Homeobox | 2 | 2019 | 72 | 0.300 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 92 | 0.300 |
Why?
|
| Repressor Proteins | 3 | 2020 | 866 | 0.290 |
Why?
|
| RNA Splicing | 2 | 2010 | 250 | 0.290 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 495 | 0.290 |
Why?
|
| 5-Methylcytosine | 3 | 2018 | 34 | 0.290 |
Why?
|
| Interferon-gamma | 1 | 2010 | 539 | 0.280 |
Why?
|
| Insulator Elements | 1 | 2007 | 3 | 0.280 |
Why?
|
| Myocardium | 4 | 2016 | 1057 | 0.280 |
Why?
|
| Cytoplasm | 2 | 2019 | 303 | 0.280 |
Why?
|
| Computational Biology | 4 | 2021 | 885 | 0.280 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2007 | 43 | 0.280 |
Why?
|
| Lysine | 2 | 2020 | 204 | 0.280 |
Why?
|
| Cell Survival | 3 | 2009 | 892 | 0.280 |
Why?
|
| Lentivirus | 1 | 2007 | 86 | 0.270 |
Why?
|
| Disease Models, Animal | 7 | 2025 | 4746 | 0.270 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1158 | 0.260 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 226 | 0.260 |
Why?
|
| Genetic Vectors | 2 | 2007 | 967 | 0.260 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 165 | 0.260 |
Why?
|
| Databases, Genetic | 2 | 2013 | 500 | 0.260 |
Why?
|
| Transduction, Genetic | 2 | 2007 | 296 | 0.250 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 68 | 0.250 |
Why?
|
| Thy-1 Antigens | 1 | 2005 | 23 | 0.250 |
Why?
|
| Hepatocytes | 2 | 2004 | 230 | 0.240 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 523 | 0.240 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 496 | 0.240 |
Why?
|
| Software | 3 | 2017 | 733 | 0.240 |
Why?
|
| Neurons | 6 | 2019 | 2033 | 0.240 |
Why?
|
| Transcription, Genetic | 6 | 2019 | 1754 | 0.240 |
Why?
|
| Embryo Research | 1 | 2005 | 9 | 0.240 |
Why?
|
| Cell Movement | 2 | 2010 | 919 | 0.230 |
Why?
|
| Endothelium, Vascular | 4 | 2003 | 510 | 0.230 |
Why?
|
| Swine, Miniature | 2 | 2002 | 53 | 0.230 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2020 | 310 | 0.230 |
Why?
|
| RNA, Messenger | 4 | 2015 | 2896 | 0.230 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2024 | 38 | 0.230 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2024 | 11 | 0.230 |
Why?
|
| Disease Progression | 2 | 2025 | 2231 | 0.230 |
Why?
|
| Rett Syndrome | 2 | 2020 | 292 | 0.230 |
Why?
|
| Erythroid Precursor Cells | 2 | 2003 | 24 | 0.230 |
Why?
|
| Cell Count | 4 | 2010 | 255 | 0.220 |
Why?
|
| Immunophenotyping | 5 | 2021 | 341 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 988 | 0.220 |
Why?
|
| NADH Dehydrogenase | 1 | 2004 | 6 | 0.220 |
Why?
|
| Phagocytosis | 1 | 2025 | 194 | 0.220 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2004 | 107 | 0.220 |
Why?
|
| Mutation, Missense | 3 | 2021 | 923 | 0.220 |
Why?
|
| Genomic Instability | 3 | 2019 | 243 | 0.220 |
Why?
|
| Oxidative Stress | 2 | 2024 | 860 | 0.220 |
Why?
|
| Heterochromatin | 1 | 2023 | 49 | 0.210 |
Why?
|
| Muscle Cells | 1 | 2003 | 27 | 0.210 |
Why?
|
| Thymocytes | 2 | 2021 | 9 | 0.210 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2024 | 45 | 0.210 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 110 | 0.210 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 3970 | 0.210 |
Why?
|
| Liver | 4 | 2010 | 1848 | 0.210 |
Why?
|
| Polymerase Chain Reaction | 3 | 2006 | 1632 | 0.210 |
Why?
|
| Liver Regeneration | 1 | 2003 | 39 | 0.210 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 842 | 0.200 |
Why?
|
| Cell Self Renewal | 3 | 2025 | 50 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 179 | 0.200 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2020 | 37 | 0.200 |
Why?
|
| Artifacts | 1 | 2004 | 112 | 0.200 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 153 | 0.200 |
Why?
|
| Sequence Analysis, Protein | 1 | 2003 | 49 | 0.200 |
Why?
|
| Adenosine Triphosphatases | 1 | 2023 | 200 | 0.200 |
Why?
|
| Multiple Myeloma | 1 | 2025 | 200 | 0.200 |
Why?
|
| Cytokines | 4 | 2019 | 1396 | 0.200 |
Why?
|
| Embryo, Mammalian | 2 | 2024 | 464 | 0.200 |
Why?
|
| Gene Deletion | 3 | 2018 | 809 | 0.200 |
Why?
|
| Gene Knockout Techniques | 3 | 2019 | 138 | 0.200 |
Why?
|
| Female | 28 | 2025 | 71345 | 0.190 |
Why?
|
| Mammary Glands, Animal | 2 | 2003 | 476 | 0.190 |
Why?
|
| Transcription Factors | 4 | 2020 | 2700 | 0.190 |
Why?
|
| Gene Silencing | 4 | 2019 | 251 | 0.190 |
Why?
|
| Physical Conditioning, Animal | 1 | 2023 | 99 | 0.190 |
Why?
|
| Myelopoiesis | 2 | 2020 | 13 | 0.190 |
Why?
|
| Monocytes | 1 | 2004 | 361 | 0.190 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 316 | 0.190 |
Why?
|
| Adipogenesis | 1 | 2022 | 79 | 0.180 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 17 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2932 | 0.180 |
Why?
|
| Models, Biological | 4 | 2014 | 1533 | 0.180 |
Why?
|
| RNA Interference | 1 | 2003 | 544 | 0.180 |
Why?
|
| Blood Vessels | 1 | 2001 | 107 | 0.180 |
Why?
|
| Interferon-alpha | 2 | 2015 | 248 | 0.180 |
Why?
|
| Amino Acid Sequence | 5 | 2012 | 2785 | 0.180 |
Why?
|
| K562 Cells | 2 | 2020 | 100 | 0.180 |
Why?
|
| Myocardial Ischemia | 2 | 2001 | 362 | 0.180 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2020 | 13 | 0.180 |
Why?
|
| Discoidin Domain Receptors | 1 | 2020 | 3 | 0.180 |
Why?
|
| Gene Frequency | 1 | 2003 | 777 | 0.180 |
Why?
|
| Transplantation, Homologous | 2 | 2002 | 692 | 0.180 |
Why?
|
| Down-Regulation | 3 | 2019 | 715 | 0.180 |
Why?
|
| Male | 25 | 2025 | 65619 | 0.170 |
Why?
|
| Genetic Techniques | 1 | 2021 | 109 | 0.170 |
Why?
|
| Short Stature Homeobox Protein | 1 | 2020 | 11 | 0.170 |
Why?
|
| Hematopoietic System | 2 | 2010 | 7 | 0.170 |
Why?
|
| Sequence Alignment | 4 | 2010 | 633 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 458 | 0.170 |
Why?
|
| Erythroid Cells | 2 | 2020 | 24 | 0.170 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 317 | 0.170 |
Why?
|
| Macrophages | 2 | 2004 | 709 | 0.170 |
Why?
|
| Burkitt Lymphoma | 1 | 2021 | 142 | 0.170 |
Why?
|
| Adenoviridae | 1 | 2003 | 609 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 67 | 0.170 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2024 | 453 | 0.170 |
Why?
|
| Smoke | 1 | 2020 | 67 | 0.170 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2020 | 63 | 0.160 |
Why?
|
| Immunohistochemistry | 5 | 2011 | 1760 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2010 | 65 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 432 | 0.160 |
Why?
|
| Microglia | 2 | 2025 | 133 | 0.160 |
Why?
|
| Time Factors | 5 | 2016 | 6562 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2020 | 62 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 104 | 0.160 |
Why?
|
| GABAergic Neurons | 1 | 2020 | 64 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 71 | 0.160 |
Why?
|
| Mice, Mutant Strains | 4 | 2013 | 400 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 227 | 0.160 |
Why?
|
| Mycobacterium avium | 2 | 2010 | 16 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 541 | 0.160 |
Why?
|
| Lymphocytes | 3 | 2016 | 440 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2019 | 13 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2006 | 1610 | 0.160 |
Why?
|
| Methylation | 2 | 2016 | 231 | 0.160 |
Why?
|
| Hematologic Tests | 1 | 2019 | 37 | 0.150 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2020 | 170 | 0.150 |
Why?
|
| Serine | 1 | 2020 | 184 | 0.150 |
Why?
|
| Cell Nucleolus | 1 | 2019 | 50 | 0.150 |
Why?
|
| DNA Primers | 2 | 2011 | 671 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2012 | 1138 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 383 | 0.150 |
Why?
|
| Hydrazines | 1 | 2018 | 34 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 110 | 0.150 |
Why?
|
| Karyopherins | 1 | 2018 | 37 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 159 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 790 | 0.150 |
Why?
|
| Aged | 8 | 2025 | 21619 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2010 | 177 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 714 | 0.140 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 198 | 0.140 |
Why?
|
| Protein Domains | 1 | 2019 | 249 | 0.140 |
Why?
|
| Tenericutes | 1 | 2017 | 2 | 0.140 |
Why?
|
| Immune System | 2 | 2009 | 98 | 0.140 |
Why?
|
| Oncogenes | 1 | 2018 | 179 | 0.140 |
Why?
|
| Triazoles | 1 | 2018 | 142 | 0.140 |
Why?
|
| Microinjections | 1 | 2017 | 51 | 0.140 |
Why?
|
| Protein Transport | 1 | 2019 | 386 | 0.140 |
Why?
|
| Proteolysis | 1 | 2018 | 191 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 871 | 0.140 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 607 | 0.140 |
Why?
|
| Cytosine | 2 | 2014 | 59 | 0.140 |
Why?
|
| Metabolome | 1 | 2020 | 312 | 0.140 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 134 | 0.140 |
Why?
|
| Sulfites | 1 | 2017 | 31 | 0.140 |
Why?
|
| Age Factors | 3 | 2011 | 2971 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2008 | 141 | 0.130 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2016 | 8 | 0.130 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2016 | 13 | 0.130 |
Why?
|
| Osteogenesis | 2 | 2011 | 167 | 0.130 |
Why?
|
| Radiation Chimera | 2 | 2010 | 18 | 0.130 |
Why?
|
| Kinetics | 2 | 2011 | 1350 | 0.130 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 5 | 0.130 |
Why?
|
| Gene Expression | 4 | 2012 | 1614 | 0.130 |
Why?
|
| DNA | 1 | 2022 | 1663 | 0.130 |
Why?
|
| Metabolomics | 1 | 2020 | 455 | 0.130 |
Why?
|
| RNA, Antisense | 1 | 2016 | 35 | 0.130 |
Why?
|
| Genetic Drift | 1 | 2015 | 23 | 0.130 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 55 | 0.130 |
Why?
|
| Cell Nucleus | 1 | 2018 | 688 | 0.120 |
Why?
|
| Genetic Linkage | 2 | 2007 | 480 | 0.120 |
Why?
|
| Lethal Dose 50 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 391 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 136 | 0.120 |
Why?
|
| Thrombocythemia, Essential | 1 | 2015 | 30 | 0.120 |
Why?
|
| Receptor, Notch1 | 2 | 2018 | 79 | 0.120 |
Why?
|
| Phosphorylation | 3 | 2020 | 1701 | 0.120 |
Why?
|
| Polycythemia Vera | 1 | 2015 | 39 | 0.120 |
Why?
|
| Selection, Genetic | 1 | 2015 | 168 | 0.120 |
Why?
|
| Base Sequence | 5 | 2013 | 3169 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 100 | 0.120 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 317 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2014 | 26 | 0.110 |
Why?
|
| Hydroxyurea | 1 | 2015 | 86 | 0.110 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2014 | 18 | 0.110 |
Why?
|
| Brain | 4 | 2025 | 3206 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 807 | 0.110 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2014 | 37 | 0.110 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 2014 | 372 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 232 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2007 | 394 | 0.110 |
Why?
|
| Spleen | 2 | 2010 | 291 | 0.110 |
Why?
|
| Transcription Factor 4 | 1 | 2013 | 12 | 0.110 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2013 | 13 | 0.100 |
Why?
|
| Ataxins | 1 | 2013 | 114 | 0.100 |
Why?
|
| Genotype | 2 | 2011 | 2804 | 0.100 |
Why?
|
| Crosses, Genetic | 2 | 2004 | 170 | 0.100 |
Why?
|
| Genes, Dominant | 1 | 2013 | 254 | 0.100 |
Why?
|
| Staining and Labeling | 3 | 2006 | 187 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 215 | 0.100 |
Why?
|
| Transcriptome | 4 | 2023 | 1119 | 0.100 |
Why?
|
| beta Catenin | 1 | 2014 | 229 | 0.100 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 89 | 0.100 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2012 | 2 | 0.100 |
Why?
|
| Middle Aged | 8 | 2025 | 29237 | 0.100 |
Why?
|
| Lymphopoiesis | 1 | 2012 | 10 | 0.100 |
Why?
|
| Stem Cell Niche | 2 | 2023 | 58 | 0.100 |
Why?
|
| Ataxin-1 | 1 | 2013 | 162 | 0.100 |
Why?
|
| Phylogeny | 2 | 2025 | 786 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2003 | 1068 | 0.100 |
Why?
|
| Coloring Agents | 1 | 2012 | 81 | 0.100 |
Why?
|
| Blotting, Southern | 2 | 2011 | 222 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 4 | 2010 | 196 | 0.100 |
Why?
|
| Mutation Rate | 1 | 2012 | 73 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 2 | 2005 | 352 | 0.090 |
Why?
|
| Binding Sites | 1 | 2015 | 1365 | 0.090 |
Why?
|
| Skin | 1 | 2015 | 554 | 0.090 |
Why?
|
| Phosphorylcholine | 1 | 2011 | 26 | 0.090 |
Why?
|
| Germ Cells | 3 | 2022 | 202 | 0.090 |
Why?
|
| CD48 Antigen | 1 | 2011 | 2 | 0.090 |
Why?
|
| Receptors, Cytokine | 1 | 2011 | 69 | 0.090 |
Why?
|
| beta-Galactosidase | 2 | 2002 | 150 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2003 | 676 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2012 | 238 | 0.090 |
Why?
|
| Graft Survival | 3 | 2003 | 557 | 0.090 |
Why?
|
| Mammals | 2 | 2023 | 277 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 528 | 0.090 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2011 | 95 | 0.090 |
Why?
|
| Blood Cell Count | 1 | 2011 | 70 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2010 | 5 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2007 | 1060 | 0.090 |
Why?
|
| p21-Activated Kinases | 1 | 2011 | 58 | 0.090 |
Why?
|
| Erythropoiesis | 2 | 2010 | 43 | 0.090 |
Why?
|
| Disease | 1 | 2012 | 134 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 80 | 0.090 |
Why?
|
| Intestines | 1 | 2015 | 612 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2011 | 63 | 0.090 |
Why?
|
| Rats | 2 | 2016 | 3874 | 0.090 |
Why?
|
| Antigens | 1 | 2011 | 157 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 86 | 0.090 |
Why?
|
| Forecasting | 2 | 2002 | 375 | 0.090 |
Why?
|
| Adult | 9 | 2025 | 31851 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 214 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2002 | 243 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 92 | 0.080 |
Why?
|
| Transplantation Chimera | 2 | 2007 | 42 | 0.080 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 201 | 0.080 |
Why?
|
| Interferons | 1 | 2011 | 145 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2011 | 646 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 294 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 355 | 0.080 |
Why?
|
| Prognosis | 2 | 2021 | 5065 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 41 | 0.080 |
Why?
|
| CD40 Ligand | 1 | 2010 | 65 | 0.080 |
Why?
|
| Twist-Related Protein 1 | 1 | 2009 | 39 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 125 | 0.080 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2009 | 9 | 0.080 |
Why?
|
| Species Specificity | 2 | 2002 | 571 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2020 | 789 | 0.080 |
Why?
|
| Radiation, Ionizing | 1 | 2009 | 43 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 382 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2011 | 630 | 0.080 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 710 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2010 | 189 | 0.070 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Haplotypes | 1 | 2010 | 561 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2010 | 342 | 0.070 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2010 | 214 | 0.070 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 59 | 0.070 |
Why?
|
| Autophagy | 1 | 2011 | 421 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2508 | 0.070 |
Why?
|
| Luciferases, Firefly | 1 | 2007 | 13 | 0.070 |
Why?
|
| Osteoblasts | 2 | 2011 | 164 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 1834 | 0.070 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2007 | 29 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2011 | 287 | 0.070 |
Why?
|
| Chromosomes, Mammalian | 1 | 2007 | 44 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2014 | 505 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 93 | 0.070 |
Why?
|
| P-Selectin | 1 | 2007 | 81 | 0.070 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 124 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 522 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2007 | 26 | 0.070 |
Why?
|
| Calibration | 1 | 2007 | 100 | 0.070 |
Why?
|
| Quality Control | 1 | 2007 | 129 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1021 | 0.070 |
Why?
|
| Swine | 2 | 2002 | 1214 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2007 | 223 | 0.060 |
Why?
|
| Integrases | 1 | 2007 | 163 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 3057 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 815 | 0.060 |
Why?
|
| Whole-Body Irradiation | 2 | 2003 | 61 | 0.060 |
Why?
|
| Retroviridae | 1 | 2006 | 198 | 0.060 |
Why?
|
| Teratoma | 1 | 2007 | 130 | 0.060 |
Why?
|
| Endoglin | 1 | 2006 | 22 | 0.060 |
Why?
|
| Receptor, TIE-2 | 1 | 2006 | 13 | 0.060 |
Why?
|
| Restriction Mapping | 3 | 2003 | 192 | 0.060 |
Why?
|
| Neutropenia | 1 | 2007 | 199 | 0.060 |
Why?
|
| Protein Folding | 1 | 2007 | 225 | 0.060 |
Why?
|
| Anemia | 1 | 2010 | 347 | 0.060 |
Why?
|
| Mitoxantrone | 2 | 2004 | 27 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1252 | 0.060 |
Why?
|
| Melphalan | 1 | 2025 | 45 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 417 | 0.060 |
Why?
|
| Codon | 1 | 2005 | 108 | 0.060 |
Why?
|
| Escherichia coli Proteins | 1 | 2007 | 306 | 0.060 |
Why?
|
| Research | 2 | 2007 | 270 | 0.060 |
Why?
|
| Parabiosis | 1 | 2004 | 3 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 486 | 0.060 |
Why?
|
| Homozygote | 2 | 2005 | 559 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2025 | 286 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2004 | 398 | 0.060 |
Why?
|
| Editorial Policies | 1 | 2005 | 54 | 0.060 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2004 | 7 | 0.060 |
Why?
|
| Cyclophilin A | 1 | 2024 | 15 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2005 | 352 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 397 | 0.050 |
Why?
|
| Myosins | 1 | 2004 | 47 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 151 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2004 | 118 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 100 | 0.050 |
Why?
|
| Electroporation | 1 | 2003 | 33 | 0.050 |
Why?
|
| Longevity | 1 | 2025 | 158 | 0.050 |
Why?
|
| Integrin alpha6beta1 | 1 | 2003 | 2 | 0.050 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2003 | 12 | 0.050 |
Why?
|
| Complement Activation | 1 | 2003 | 53 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2004 | 89 | 0.050 |
Why?
|
| Mammary Glands, Human | 1 | 2003 | 84 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 1439 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2003 | 109 | 0.050 |
Why?
|
| Hybridomas | 1 | 2002 | 41 | 0.050 |
Why?
|
| Blood Component Removal | 1 | 2002 | 35 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 337 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2004 | 456 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 369 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1047 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 133 | 0.050 |
Why?
|
| Molecular Probes | 1 | 2002 | 31 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 7184 | 0.050 |
Why?
|
| Benchmarking | 1 | 2003 | 148 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2001 | 27 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 926 | 0.050 |
Why?
|
| Ikaros Transcription Factor | 1 | 2021 | 32 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 53 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 1124 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 433 | 0.050 |
Why?
|
| Wound Healing | 2 | 2003 | 496 | 0.050 |
Why?
|
| Verapamil | 2 | 2003 | 58 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2004 | 1127 | 0.040 |
Why?
|
| Anemia, Macrocytic | 1 | 2020 | 8 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 370 | 0.040 |
Why?
|
| Muscle Development | 1 | 2001 | 76 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 912 | 0.040 |
Why?
|
| Heterografts | 1 | 2021 | 194 | 0.040 |
Why?
|
| RNA | 1 | 2004 | 602 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2001 | 263 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2022 | 222 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 137 | 0.040 |
Why?
|
| Leukocyte Count | 3 | 2007 | 259 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2002 | 170 | 0.040 |
Why?
|
| Transfection | 1 | 2002 | 1090 | 0.040 |
Why?
|
| Phosphopeptides | 1 | 2020 | 28 | 0.040 |
Why?
|
| Adolescent | 4 | 2025 | 20480 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2020 | 94 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2020 | 30 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.040 |
Why?
|
| Leukapheresis | 1 | 1999 | 14 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 107 | 0.040 |
Why?
|
| CD5 Antigens | 2 | 2010 | 36 | 0.040 |
Why?
|
| Heart | 1 | 2005 | 755 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2001 | 231 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2020 | 90 | 0.040 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2001 | 155 | 0.040 |
Why?
|
| RNA Polymerase II | 1 | 2020 | 102 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 163 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2000 | 179 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1101 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 239 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2024 | 607 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 172 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 231 | 0.040 |
Why?
|
| Thymine DNA Glycosylase | 1 | 2019 | 3 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2025 | 14748 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 444 | 0.040 |
Why?
|
| Antigens, CD19 | 2 | 2010 | 180 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 738 | 0.040 |
Why?
|
| Acute Disease | 1 | 2001 | 1184 | 0.040 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 1084 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1464 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 244 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2162 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2002 | 939 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 727 | 0.030 |
Why?
|
| ras Proteins | 1 | 2018 | 144 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 867 | 0.030 |
Why?
|
| Young Adult | 2 | 2025 | 9872 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 712 | 0.030 |
Why?
|
| Glutarates | 1 | 2016 | 38 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 216 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 506 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1997 | 513 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1997 | 313 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 182 | 0.030 |
Why?
|
| Granulocytes | 2 | 2007 | 70 | 0.030 |
Why?
|
| Radiation Protection | 1 | 1996 | 57 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 695 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 438 | 0.030 |
Why?
|
| Muscles | 1 | 2015 | 307 | 0.030 |
Why?
|
| Child | 3 | 2025 | 25678 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 2064 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 134 | 0.030 |
Why?
|
| Polycomb-Group Proteins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 248 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 2004 | 118 | 0.030 |
Why?
|
| Genes, Developmental | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 172 | 0.030 |
Why?
|
| COS Cells | 1 | 2013 | 283 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 127 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2013 | 298 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1992 | 21 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2012 | 58 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 261 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2012 | 45 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 412 | 0.020 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2012 | 81 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6629 | 0.020 |
Why?
|
| Homologous Recombination | 1 | 2012 | 100 | 0.020 |
Why?
|
| Autoantigens | 1 | 1992 | 118 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 486 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1067 | 0.020 |
Why?
|
| DNA Transposable Elements | 1 | 1992 | 188 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2012 | 165 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 246 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 577 | 0.020 |
Why?
|
| Spermatozoa | 1 | 2012 | 241 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Vidarabine | 1 | 2010 | 78 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 68 | 0.020 |
Why?
|
| Infant | 2 | 2004 | 13107 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2009 | 125 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2011 | 285 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 162 | 0.020 |
Why?
|
| Remission Induction | 1 | 2009 | 308 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1831 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 144 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 315 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2011 | 406 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 60 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 328 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 49 | 0.020 |
Why?
|
| Guided Tissue Regeneration | 1 | 2007 | 3 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 142 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 159 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1726 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 166 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 1992 | 836 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 335 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 751 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 1084 | 0.010 |
Why?
|
| Presenilin-2 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2004 | 38 | 0.010 |
Why?
|
| Presenilin-1 | 1 | 2004 | 57 | 0.010 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2004 | 62 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 21 | 0.010 |
Why?
|
| Mice, Inbred mdx | 1 | 2003 | 46 | 0.010 |
Why?
|
| Myoblasts | 1 | 2003 | 36 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 62 | 0.010 |
Why?
|
| Yolk Sac | 1 | 2003 | 20 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 367 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 109 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 116 | 0.010 |
Why?
|
| Cobra Cardiotoxin Proteins | 1 | 2002 | 5 | 0.010 |
Why?
|
| Endothelium | 1 | 2003 | 71 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2003 | 178 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 992 | 0.010 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2003 | 172 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2006 | 1243 | 0.010 |
Why?
|
| Antigens, CD7 | 1 | 2000 | 11 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2002 | 317 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 404 | 0.010 |
Why?
|
| Fetus | 1 | 2003 | 600 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2004 | 539 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2007 | 12957 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1311 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2002 | 721 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 1329 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 2380 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 1992 | 52 | 0.010 |
Why?
|
| Centromere Protein B | 1 | 1992 | 2 | 0.010 |
Why?
|
| Nucleotidyltransferases | 1 | 1992 | 46 | 0.010 |
Why?
|
| Transposases | 1 | 1992 | 45 | 0.010 |
Why?
|
| Cell Death | 1 | 1992 | 249 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1992 | 119 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 1992 | 207 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 7487 | 0.010 |
Why?
|
| Heterozygote | 1 | 1992 | 716 | 0.010 |
Why?
|